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The G1 cyclins play a pivotal role in regulation of cell differenti-
ation and proliferation. The mechanisms underlying their cell-
specific roles are incompletely understood. Here, we show that
a G1 cyclin, cyclin D2 (CycD2), enhances the activity of transcription
factor GATA4, a key regulator of cardiomyocyte growth and dif-
ferentiation. GATA4 recruits CycD2 to its target promoters, and
their interaction results in synergistic activation of GATA-depen-
dent transcription. This effect is specific to CycD2 because CycD1 is
unable to potentiate activity of GATA4 and is CDK-independent.
GATA4 physically interacts with CycD2 through a discreet N-termi-
nal activation domain that is essential for the cardiogenic activity
of GATA4. Human mutations in this domain that are linked to
congenital heart disease interfere with CycD2-GATA4 synergy.
Cardiogenesis assays in Xenopus embryos indicate that CycD2
enhances the cardiogenic function of GATA4. Together, our data
uncover a role for CycD2 as a cardiogenic coactivator of GATA4
and suggest a paradigm for cell-specific effects of cyclin Ds.
GATA transcription factors | heart development | heart repair
D-type cyclins [Cyclin D1 (CycD1), CycD2, and CycD3] andtheir partners, the cyclin-dependent kinases (CDKs), are
important regulators of the cell cycle (1), connecting the cell
cycle machinery with the extracellular environment. In response
to mitogenic signals, cyclin Ds associate with CDK4 and CDK6,
phosphorylate the tumor suppressor retinoblastoma protein Rb,
along with the family members p107 and p130, and, together
with cyclin E/A-CDK2 complexes, control the G1/S-phase tran-
sition in the cell cycle (1, 2). In addition to the Rb protein family,
cyclin D–CDK4 complex was found to phosphorylate other
transcription factors involved in cell proliferation/arrest, such as
the transcription factor SMAD3 and the myb like transcription
factor, DMP1 (3, 4). Moreover, Cyclin Ds have been shown to
interact with transcription coactivators/corepressors such as
CBP, p300, P/CAF and HDACs (5–8) and a repressor domain
distinct from the CDK regulatory domain has been identified on
CycD1 (9). As such, Cyclin Ds play important roles as CDK-
dependent and -independent transcriptional modulators. Most
transcription studies so far have focused on CycD1 but some of
the reported interactions appear to be specific to a particular
Cyclin D family member (10). In other cases, interaction of dif-
ferent Cyclin Ds with the same transcription factor, as in the case
of the peroxisome proliferator-activated receptor (PPAR)γ, leads
to opposing outcomes (11, 12). Although the mechanisms under-
lying these differential effects remain uncertain, the findings, to-
gether with the distinct expression pattern of the three Cyclin Ds
(1), have raised intriguing questions regarding cell-specific func-
tions of Cyclin Ds in normal development and disease.
In addition to cell cycle regulation, Cyclin Ds participate in
several other cellular processes, including hormone regulation
(13, 14) and cell differentiation; for example, CycD1 (but not
CycD2) promotes neurogenesis in a cell cycle-independent manner
(15), whereas CycD3 appears to play a unique function in lym-
phocyte development (16) and adipogenesis (12). In all cases, gain
and loss of Cyclin Ds lead to profound changes in gene expression
through transcriptional mechanisms that remain incompletely un-
derstood. The production of transgenic mice homozygous for one
or more Cyclin D allele has confirmed the requirement for specific
Cyclin Ds in organ development (17). CycD2 appears to play an
important role in the embryonic and postnatal heart, where it has
been shown to be a direct target of the cardiogenic transcription
factor GATA4 (18, 19). CycD2 has been linked to cardiomyocyte
regeneration (20), hypertrophy (21), and stress response (22).
In the present study, we show that CycD2 but not CycD1 is
a potent coactivator of GATA4, a critical cardiac regulator.
CycD2 physically interacts with GATA4, is recruited to GATA4
target promoters, and enhances GATA4-dependent transcrip-
tion. Moreover, CycD2 potentiates GATA4-dependent cardio-
genesis but does not affect other cell fates induced by GATA4,
including endoderm. The data provide a mechanism that may
underlie, at least in part, cell specificity of Cyclin Ds and a ra-
tionale for targeting cell cycle proteins for cardiac repair.
Results
CycD2 Is a GATA4 Transcriptional Coactivator. CycD2 is a direct
GATA4 target in the heart (18, 19), where it is coexpressed with
GATA4 in fetal and neonate cardiomyocytes. In the mouse
heart, CycD2 transcripts have been reported as early as embry-
onic day (E) 9 in the developing ventricles (23). Importantly,
CycD2 transcripts were detected by PCR in E7.5 embryos and
were localized in the primitive streak and in mesodermal cells
migrating from it; these cells were not positive for CycD1 (24).
We carried out immunohistochemical analysis of CycD2 and
GATA4 using consecutive embryonic tissue sections. As shown
in Fig. S1, CycD2 and GATA4 colocalized in the mesothelial
cells of the future cardiogenic plate at E7.5 and within numerous
myocardial and cushion cells in E9.5 and later-stage embryos.
We extended our analysis to Xenopus, where, in addition to the
previously described prominent CNS expression (25), we detec-
ted CycD2 in the developing heart of stage 30 Xenopus embryos,
around the onset of cardiomyocyte differentiation (Fig. S1).
Significance
Cyclin D2 is a cell cycle regulator with spatially restricted ex-
pression. Loss and gain of function in animal models also re-
vealed a role in cell differentiation, but the mechanisms
underlying this are incompletely understood. The cardiogenic
transcription factor GATA4 is an upstream regulator of cyclin
D2. We show that GATA4 and cyclinD2 are part of a forward
reinforcing loop in which cyclin D2 feeds back to enhance
GATA4 activity through direct interaction. Mutations in GATA4
that abrogate cyclin D2 interactions are associated with human
congenital heart disease. The results unravel a unique transcrip-
tional role of cyclin D2 that may underlie its cell specificity. The
finding that cyclin D2 is a cardiogenic GATA4 cofactor may be
exploitable therapeutically for heart repair.
Author contributions: M.N. designed research; A.Y., B.V.L., R.D., and R.T. performed re-
search; A.Y., B.V.L., and M.N. analyzed data; A.Y., B.V.L., and M.N. wrote the paper; and
A.Y. and B.V.L. prepared the figures.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
Freely available online through the PNAS open access option.
1To whom correspondence should be addressed. E-mail: mona.nemer@uottawa.ca.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1312993111/-/DCSupplemental.
www.pnas.org/cgi/doi/10.1073/pnas.1312993111 PNAS | January 28, 2014 | vol. 111 | no. 4 | 1415–1420
D
EV
EL
O
PM
EN
TA
L
BI
O
LO
G
Y
We tested whether CycD2 affects GATA4 activity. Cotrans-
fection of CycD2 and GATA4 in National Institutes of Health
(NIH) 3T3 cells showed that CycD2 enhances GATA4 activity
on its target promoters, including Nppa and CycD2 (ccnd2) (Fig.
1A, Left and Center); CycD2 enhancement of GATA4 tran-
scription was also observed on the minimal GATA-dependent
promoter, suggesting that GATA-binding sites were sufficient to
support synergy (Fig. 1A, Right). This effect was also observed in
HL1 cells, which are mouse atrial cardiomyocytes (Fig. 1B). To
test whether in vivo CycD2 can potentiate GATA4 activity,
GATA-Luc transgenic mice were crossed with mice overexpressing
CycD2 specifically in the heart (under the control of the α-MHC
promoter). Quantitative PCR analysis confirmed that ccnd2 tran-
scripts are specifically up-regulated in the heart but have no ef-
fect on GATA4 encoding mRNA levels (Fig. 1C), consistent
with our published results (18). Up-regulation of ccnd2 resulted in
a twofold higher GATA-dependent luciferase transcription spe-
cifically in the heart of double transgenics but not in other organs
exhibiting GATA activity like liver (Fig. 1C). Interestingly, in-
creased GATA activity was not associated with increased phos-
phorylation of S105, the major MAPK target residue on GATA4
(Fig. S2). To further confirm that CycD2 associates with GATA-
binding sites on GATA4 target promoters, we performed chro-
matin immunoprecipitation (ChIP) assays on the endogenous
ccnd2 gene using cell lines with stable overexpression of Flag-
CycD2. As shown in Fig. 1D, CycD2 was enriched twofold on the
−99 GATA site relative to the Dessert gene (used as internal
control). GATA4 was also enriched at this site, consistent with our
previous results (18).
These results suggested that GATA4 could recruit CycD2 to
target promoters. To test this possibility, we performed coim-
munoprecipitation assays using cells expressing Flag-GATA4 and
HA-CycD2 alone or in combination. As shown in Fig. 1E, CycD2
coimmunoprecipitated with GATA4. Of note, CycD2 did not
increase levels of nuclear GATA4 nor did it result in detectable
changes in subcellular distribution (Fig. 1E, Left, and Fig. 1F).
Next, we tested whether enhancement of GATA4 transcriptional
activity could also be observed with the related CycD1. Cotrans-
fection of GATA4 with CycD1 showed that CycD1 is unable to
enhance GATA4-dependent transcription (Fig. 2A); in fact, CycD1
inhibited GATA4 activity in a dose-dependent manner (Fig. 2A,
Right). This result is consistent with a recent report showing that
cardiac-specific CycD1 overexpression in mice reduces GATA4
protein levels and inhibits cardiomyocyte differentiation (26).
The specificity of CycD2/GATA interaction to GATA4 was
also checked by testing the ability of CycD2 to synergize with the
hematopoietic GATA family members GATA1, -2 , and -3, as
well as the other two cardiac members, GATA5 and GATA6. Fig.
2B shows that CycD2 produced no transcriptional enhancement
when combined with GATA1–3; a modest but reproducible en-
hancement of the activity of the other cardiac GATA proteins was
detected. Thus, CycD2 appears to enhance GATA4 activity in
preference over other GATA family members.
A Discrete GATA4 N-Terminal Domain Is Required for CycD2 Synergy.
To determine which region of GATA4 is required for CycD2
interaction, we carried out a structure–function analysis of GATA4.
Mutant proteins that harbored various C-terminal or N-terminal
deletions were used. All mutants were tested for their ability to be
expressed in the nucleus at similar levels and bind DNA using
Western blot analysis and electrophoretic mobility-shift assays (Fig.
S3). As expected, N- and C-terminal GATA4 deletions reduced
transcriptional activity. When the same constructs were tested for
synergy with CycD2, removal of the C-terminal region had mini-
mal effect on the synergy. Removal of the first 145 aa reduced but
did not abrogate the synergy. However, removal of the first 174
aa abolished the synergy, suggesting that amino acids 145–174 on
the GATA4 protein are critical for interaction with CycD2 (Fig.
2C). To determine whether the GATA4 domain required for
synergy is involved in physical interaction with CycD2, in vitro
pull-down assays were performed with GST- produced N- and
C-terminal GATA4 fusion proteins and in vitro-translated CycD2.
Fig. 3A shows that CycD2 is able to physically interact with the
N- but not C-terminal region of GATA4. Moreover, a GATA4
fragment containing amino acids 130–170 was sufficient for phys-
ical interaction with CycD2 (Fig. 3B).
The 145- to 174-aa region of GATA4 lies within the second
N-terminal transactivation domain and is conserved across GATA4
proteins from different species from zebrafish to human but not
in other members of the GATA family (Fig. 3 C and D). Two
conserved amino acids in this region, S160 and P163, have been
reported mutated in humans with congenital heart defects (27–
30). We tested the effect of S160 mutation on interaction with
CycD2. As shown in Fig. 3B, mutation S160G greatly reduced
physical interaction of GATA4 with CycD2. We produced GATA4
proteins with mutations on S160 and P163. As shown in Fig. S4, the
mutant proteins retained their ability to be expressed and bind
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Fig. 1. GATA4 and Cyclin D interaction. (A and B) Transient transactivation
of CycD2 (ccnd2), Nppa, and the minimal GATA promoter by GATA4 and
CycD2 in NIH 3T3 cells (A) and in HL-1 atrial cardiomyocytes (B); 250 and 500
ng of GATA4 expression vector and 3 and 4 μg of CycD2 expression vector
were used in the case of NIH cells and 25 ng of GATA4 and 0.5, 1, and 3 μg of
CycD2 expression vectors were used in the case of HL-1 cells. (C) Transcript
levels of luciferase, ccnd2, and Gata4 in the heart and liver of GATA-Luc
transgenic mice crossed with HA-ccnd2 mice. Note the increase of luciferase
mRNA levels of CycD2.GATA-Luc mice relative to those of GATA-Luc mice
specifically in the heart (Left). (Center) Control to show the overexpression
of CycD2 in the hearts of CycD2.GATA-Luc mice but not in the liver. (Right)
No effect of CycD2 overexpression on Gata4 mRNA levels. The results are
shown as means ± SEM (n = 3). *P < 0.05; **P < 0.01. (D) Enrichment of
CycD2 and GATA4 on CycD2 promoter, as revealed by ChIP. Dessert is used as
a negative gene. IgG is a negative control. Flag-GATA4 and Flag-CycD2
C2C12 stable cell lines were used. The results are means ± SEM (n = 3). *P <
0.05 vs. IgG. (E) CycD2 coimmunoprecipitates with GATA4 in vivo. Nuclear
extracts from 293T cells transfected with Flag-GATA4 and/or HA-CycD2 ex-
pression vectors were immunoprecipitated using an anti-Flag antibody,
separated on 8% (vol/vol) SDS/PAGE, transferred to poly(vinylidene difluoride)
(PVDF) membranes, and subjected to immunoblotting using anti-HA, anti-
CycD2, or anti-GATA4 antibodies. The results here are from one represen-
tative experiment of three. For consistency, the relevant lanes were spliced
from the same blot image and assembled in the order shown. (F) Immuno-
cytochemical analysis of 293T cells transiently transfected with 100 ng of
Flag-GATA4 with or without 1 μg of HA-CycD2. Red is GATA4 staining;
green is CycD2; blue marks nuclei (Hoechst). Note cotransfection of GATA4
with CycD2 does not affect GATA4 nuclear levels.
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DNA as well as wild-type (WT) GATA4. However, their baseline
activity, as well as their synergy with CycD2 but not with Tbx5,
were significantly attenuated (Fig. 3 E and F and Fig. S4).
Bioinformatics analysis using the Motif Scan Web site (http://
scansite.mit.edu/motifscan_seq.phtml) suggested that S160 may
be a putative CDK phosphorylation site. We tested whether S160
can be phosphorylated by CDK4 using in vitro kinase assay;
when active CDK4 kinase was incubated with N- and C-terminal
GST GATA4 fusion proteins phosphorylation of the N- but not
C-terminal GATA4 domain was detected. Incubation of CDK4
kinase with GST–N-terminal GATA4 harboring the S160G
mutation greatly reduced this phosphorylation, suggesting that
S160 is a major CDK4 phosphorylation site on GATA4 protein
(Fig. 4A). The same mutation had no impact on MAPK phos-
phorylation of the 2–207 GATA4 domain, consistent with pre-
vious studies that found S105 to be the major MAPK target in
the N-terminal domain of GATA4 (31). Interestingly, GATA4
S105 phosphorylation level was similar in the hearts of WT mice
and in those overexpressing CycD2 (18), suggesting that CycD2-
dependent phosphorylation takes place at distinct residues (Fig.
S2). Next, we tested the effect of CDK4 inhibition on GATA4
activity and synergy with CycD2. Luciferase assays performed on
NIH 3T3 cells cotransfected with increasing doses of GATA4
protein in presence of pharmacologic CDK4 inhibitors showed
reduced GATA4 activation of its target promoters (Fig. 4B).
Interestingly, CDK4 inhibition had a more modest effect on the
S160 mutant than on WT GATA4, consistent with this residue
being an important CDK4 target (Fig. 4B). These results suggest
that CDK4 kinase activity is required for maximal GATA4 tran-
scriptional activity. We checked whether CDK4 activity interferes
with GATA4-CycD2 synergy. As shown in Fig. 4C, the CDK4 in-
hibitors decreased GATA4 activation of the GATA-Luc reporter
but did not interfere with CycD2 synergy, with the fold enhancement
decreasing modestly from 2.5 to 2 in the presence of either inhibitor.
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Fig. 2. Specificity of GATA4-CycD2 interaction. (A, Left) Transient trans-
activation of GATA-dependent promoter by GATA4 and CycD1 or CycD2 in
NIH 3T3 cells; 500 ng of GATA4 and 4 μg of CycD1 or CycD2 expression
vectors were used. Note that CycD1 does not synergize but rather inhibits
GATA4 activity. #P < 0.005 vs. GATA4. (Right) Transient transactivation of
GATA-dependent promoter by GATA4 and CycD1 in NIH 3T3 cells; 10 ng of
GATA4 and 100, 200, 500, and 3,000 ng of CycD1 were used. Note that CycD1
inhibits GATA4 activity in a dose-dependent manner. (B) Transient trans-
activation of GATA-dependent promoter by GATA1, -2, -3, -4, -5, or -6 and
CycD2 in NIH 3T3 cells; 250 and 500 ng of GATA and 4 μg of CycD2 expression
vectors were used in the cases of GATA1, -2, -3, -4, and -6; 15 and 25 ng of
GATA and 1 μg of CycD2 expression vectors were used in the case of GATA5.
Note a statistically significant synergy of CycD2 with GATA4. Modest but
reproducible synergy was seen in case of GATA5 and 6. No synergy was seen
with the hematopoietic GATA members even at different doses. **P < 0.01;
#P < 0.005 vs. GATA4. (C) Structure–function analysis of GATA4/CycD2 acti-
vation of the GATA-dependent promoter. Transient transfections were
carried out in NIH 3T3 cells using the indicated GATA4 and/or CycD2 ex-
pression vectors and the GATA-Luc reporter; 250 and 500 ng of GATA4 and
4 μg of CycD2 were used. The results shown are those of one representative
experiment of three carried out in duplicates with the SD of the mean. *P <
0.05; **P < 0.01; #P < 0.005; ##P < 0.0001 vs. GATA4.
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Fig. 3. CycD2 physically interacts with N-terminal GATA4 in vitro. (A) In
vitro-translated radiolabeled CycD2 protein (or luciferase protein as a nega-
tive control) was incubated with glutathione Sepharose beads containing
GST–N-terminal GATA4 or GST–C-terminal GATA4 fusion proteins. The
bound proteins were then resolved by SDS/PAGE and revealed by autora-
diography. Note that CycD2 binds to N-terminal GATA4 (second lane). The
experiment is one representative of two. (B) Amino acids 130–170 are suf-
ficient to interact with CycD2, and S160 is required for this interaction. In
vitro-translated radiolabeled CycD2 protein were incubated with glutathi-
one Sepharose beads containing GST alone, GST–N-terminal region 2–207 of
GATA4, the same GST–N-terminal part of GATA4 harboring the S160G mu-
tation or GST–130–170 GATA4 fusion proteins. The bound proteins were
then resolved by SDS/PAGE and revealed by autoradiography. In vitro-
translated luciferase protein was used as a negative control. Note that CycD2
binds to amino acids 2–207 of GATA4 and 130–170 but not S160G mutant.
The experiment is one representative of two. (C) Schematic representation
of GATA4 protein. Note that the 145- to 174-aa region, and particularly
amino acid S160, is highly conserved among the mouse, rat, human, and
Xenopus. (D) Alignment of the CycD2-interacting domain (145–174) of hu-
man GATA4 with the other GATA members as indicated. Note that this re-
gion is highly divergent among the different GATA members. (E) Fold
synergy of CycD2 with WT (Wt) GATA4 or the indicated S160 GATA4 mutants
on Nppa promoter (Left) or GATA-dependent promoter (Right). Note the
reduced fold of synergy with both S160G and S160A. *P < 0.05 vs. Wt. (F)
Transient transactivation of Nppa promoter by WT or S160A GATA4 with or
without either CycD2 or TBX5; 250 ng of GATA4 was used with 4 μg of
CycD2; 5 ng of GATA4 was used with 50 ng of TBX5. Note the S160 mutation
attenuates synergy with CycD2 but not TBX5. *P < 0.05 vs. GATA4.
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This suggested that CycD2 was acting as a CDK4-independent
coactivator. Cyclin Ds were shown to interact with their catalytic
partners CDK4/6 through a lysine residue in the cyclin box (32).
To check whether interaction of CycD2 with GATA4 was indeed
independent of the CDK4-binding site on CycD2, we generated
a K112A CycD2 mutant. When cotransfected with GATA4, this
mutant was able to enhance GATA4 activation of a GATA-
dependent promoter in a manner similar to WT CycD2 (Fig. 4D).
Consistent with this result, the presence of both CDK4 and CycD2
with GATA4 did not produce greater activation of the GATA-Luc
reporter than either GATA4-CDK4 or GATA4-CycD2 (Fig. 4E).
CycD2 Enhances Cardiogenic Activity of GATA4. The CycD2 inter-
action domain overlaps with a region of GATA4 that was recently
found to be essential for its cardiogenic activity (33), and mutations
therein that decrease synergy with CycD2 have been associated
with congenital heart disease (Fig. 3). This raised the possibility
that CycD2 might cooperate with GATA4 in cardiogenesis.
To check the consequences of CycD2/GATA4 interaction on
cardiogenesis, we examined the ability of CycD2 to alter the
activity of GATA4 in ectodermal (animal cap) explants from
Xenopus embryos. To enhance detection of anticipated positive
effect of CycD2 on activity of GATA4, we used suboptimal
amount of GATA4 encoding mRNA (300 pg; optimal range is
400–1,000 pg) (34), together with a range of CycD2 encoding
mRNA concentrations from 10 to 500 pg to determine that the
optimal dose of CycD2 mRNA is 100 pg. As shown in Fig. 5A,
CycD2 mRNA specifically stimulated the cardiogenic activity of
GATA4, as evident by the induction of the cardiomyocyte-spe-
cific markers myosin light chain 7 (myl7) and myosin heavy chain
6 (myh6) but not the endodermal marker endodermin (a2m), the
smooth muscle actin marker (acta2), or globin, the hematopoi-
etic marker (hba1). Moreover, and consistent with its reduced
transcriptional activity, GATA4 S160 mutations that reduce
CycD2 synergy (S160G) or are associated with human congenital
heart defects (S160T) decreased GATA4-dependent induction
of cardiomyocytes (Fig. 5B) but not of markers of endoderm and
blood. In addition, the S160G mutation abrogated the ability of
CycD2 to potentiate GATA4 cardiogenesis (Fig. 5C). This was not
attributable to changes in protein levels given that nuclear ex-
pression of the mutants tested was similar to that of WT GATA4
in the explants (Fig. 5D). Collectively, these results indicate that
CycD2 can act as a coactivator of GATA4 in cardiogenesis.
Discussion
Transcription factor GATA4 is a critical regulator of heart de-
velopment and homeostasis, where it has multiple essential and
nonredundant roles in cell growth, survival, and differentiation.
Moreover, GATA4 is a cardiogenic factor that can activate the
genetic program required to convert stem and precursor cells to
the cardiogenic lineage (34–36). CycD2 is a direct GATA4
transcription target in the heart, and its cardiomyocytes up-
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Fig. 4. Phosphorylation of GATA4 at S160 is required for its transcriptional
activity. (A) In vitro CDK4 or MAPK phosphorylation of GST-GATA4 fusion
proteins. Active CDK4 kinase was able to phosphorylate N-terminal GST-
GATA4 (2–207) fusion protein (black arrow) but not GST alone, nor C-terminal
GST-GATA4 (329–440) nor N-terminal GATA4 harboring the S160G mutation.
MAPK phosphorylation of N-terminal GATA4 was not affected by S160
mutation. The experiment is one representative of three. (B) Inhibition of
CDK4 reduces GATA4 activity. (Left) NIH 3T3 cells were transiently trans-
fected with the GATA-dependent promoter and increasing doses of GATA4
expression vector (5, 10, 50, 100, and 500 ng) with or without treatment with
CDK4 inhibitor; 2 μM the indicated CDK4 inhibitor was used. The cells were
treated the following day after transfection and kept for 18 h. (Right) Effect
of the CDK4 inhibitor RO506220 on S160G GATA4 mutant. NIH 3T3 cells
were transiently transfected with Nppa-Luc and increasing doses of the in-
dicated GATA4 expression vector (10, 50, 100, and 250 ng) with or without
treatment with CDK4 inhibitor as above. Note S160G activity is affected less
prominently by CDK4 inhibitor RO506220 than its WT. *P < 0.05 vs. Wt. (C)
Inhibition of CDK4 does not affect GATA4/Cyclin D twofold synergy. NIH 3T3
cells were transiently transfected with GATA-Luc, 50 or 100 ng of GATA4,
and/or 1 μg of CycD2 expression vectors with or without treatment with
CDK4 inhibitors as above. (D) CycD2/GATA4 synergy does not require CDK-
binding site. NIH 3T3 cells were transiently transfected with GATA-Luc,
GATA4, and/or CycD2 expression vectors. K112A CycD2 mutant was prepared
by PCR-mediated mutagenesis; 50, 250, and 500 ng of GATA4 expression
vector and 1 and 4 μg of CycD2 and K112A expression vectors were used. (E)
Lack of triple synergy between CycD2, CDK4, and GATA4. NIH 3T3 cells with
transiently transfected with GATA-Luc, CDK4 (50 ng), and/or GATA4 (25 ng)
and/or CycD2 (50 ng) expression vectors. Note that fold synergy of GATA4/
CycD2 does not increase with addition of CDK4.
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Fig. 5. CycD2 potentiates cardiogenic activity of GATA4. (A) CycD2 stim-
ulates cardiogenic activity of the rat GATA4. Animal cap explants injected
with 100 pg of CycD2 mRNA, 300 pg of Gata4 mRNA (G4), or the two
combined were analyzed for expression of indicated markers at stage 34.
Myl7 and myh6 are exclusively expressed in cardiac myocytes, endodermin
(a2m) is an endodermal marker, smooth muscle actin (acta2) marks smooth
muscle, and globin (hba1) is a marker of blood. Note that stimulation of
GATA4 activity by CycD2 is restricted to induction of cardiac but not other
cell fates. (B) S160 is important for cardiogenic activity of GATA4; 400 pg of
indicated GATA4 constructs were injected. Animal explants were cultured as
above, and expression of indicated markers were determined by RT-PCR. (C)
S160 is required for stimulation of GATA4 activity by CycD2; 100 pg of CycD2
mRNA and 300 pg of the indicated GATA4 constructs were injected per
embryo. Expression of myl7, myh6, and odc1 were determined by RT-PCR.
The dotted lines between lanes in A and C indicate that the image shown
was assembled either from two gels run in parallel or derives from the same
gel after splicing out unnecessary lanes. (D) Immunofluorescence assay to
determine the nuclear localization of the indicated GATA4 constructs in
stage 6–7 embryos. Anti-GATA4 antibody was used. (Scale bar: 0.1 mm.)
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regulation in transgenic mice enhances postischemic heart repair
and rescues GATA4 haploinsufficiency (18, 20). Here, we show
that CycD2 but not CycD1 enhances transcriptional activity of
GATA4 and potentiates GATA4-dependent cardiomyogenesis.
Moreover, CycD2 interacts physically with a GATA4 N-terminal
activation domain that overlaps with a recently identified GATA4
cardiogenic domain (33). We find that mutations within this do-
main that reduce CycD2-GATA4 synergy are associated with de-
creased GATA4 cardiogenic activity and with human congenial
heart disease. Together, the results suggest the existence of a pos-
itive GATA4-CycD2 feedback loop in cardiomyocytes that may be
exploited for expansion of cardiomyogenic progenitors for heart
repair therapy.
CycD2 effect on GATA4 activity was not reproduced by
CycD1, which in fact inhibited GATA4 transcriptional activity.
This latter result is consistent with a recently published study
suggesting that CycD1 causes GATA4 degradation through
a jumonji pathway (26). However, unlike the finding of Nakajima
et al. (26), that CDK4 inhibits GATA4 activity, we find that
CDK4 enhances GATA4 activity. These discrepancies may re-
flect stage- and region-specific effects of GATA4 through dif-
ferential interactions with particular Cyclin D members. Such
differential effects of Cyclin Ds on cell fate determination have
been observed in neurogenesis where CycD1 can inhibit differ-
entiation by preventing G1 lengthening (37) and interfering with
Neuro D (38); yet, CycD1 can also promote neurogenesis in
a cell cycle independent manner (15). The differential effects of
CycD1 and -D2 on GATA4 are in line with the different effects
of the two family members when overexpressed in transgenic
hearts (20) and their distinct interaction with other cell cycle
regulators (39) including in cardiomyocytes (40). Importantly,
the finding that CycD2 cooperates with GATA4 in cardiogenesis
is consistent with the findings that up-regulated CycD2 expres-
sion in postnatal hearts is associated with increased resistance to
drug induced cardiac dysfunction (18), as well as enhanced post
ischemic repair (20). This role in cardiomyocytes is reminiscent
of the dual role of CycD2 in pancreatic and neurogenic pro-
genitor expansion and differentiation (41, 42).
The mechanism by which CycD2 enhances GATA4 activity
does not appear to require CDK4 although a CDK4 phosphor-
ylation site lies within the CycD2 interaction domain on GATA4.
First, mutation of the CDK4 interaction domain on CycD2 has
no effect on synergy; second, pharmacologic inhibition of CDK4
decreases basal GATA4 activity but has only minimal effect on
synergy with CycD2. No effect of CycD2 on GATA4 mRNA or
protein levels and subcellular distribution were detected, sug-
gesting that CycD2 affects GATA4 transcriptional activity likely
through protein–protein interactions.
Although the role of CycD2 in differentiation and homeostasis
is supported by loss- and gain-of-function in model animals
(22, 41, 42), the mechanisms underlying these effects are in-
completely understood. Unlike CycD1, whose emerging role as
a transcriptional regulator has received significant attention
lately (reviewed in ref. 43), little is known regarding CycD2
function in transcription outside regulation of the Rb pathway.
The only well-characterized CycD2 interactors are the CDKs, in
contrast to CycD1 and -D3, for which several interacting part-
ners have been reported. For instance, CycD1 has been shown to
interact with the histone acetyl transferase p300/CREB-binding
protein-associated protein (P/CAF), thus facilitating the inter-
action of P/CAF with the estrogen receptor (ER) and possibly
providing a mechanism for CycD1-stimulated ER transcriptional
activity and oncogenic potential in breast cancer (8, 44). The zinc
finger transcription factor INSM1 has also been shown to bind
to CycD1, leading to cell cycle arrest and inhibition of prolif-
eration, thereby suggesting a possible mechanism for pancreatic
endocrine cell differentiation where INSM1 plays an important
role (45). CycD3 was shown to be a coactivator of the nuclear
receptor PPARγ in adipogenesis (12). CycD1 has been repor-
ted to inhibit PPARγ-mediated adipogenesis via HDAC re-
cruitment (6). CycD1/CDK4 was also shown to phosphorylate
and inhibit the DNA-binding ability of BRCA1 in breast cancer
cells (46). Interestingly, a genome-wide location approach re-
vealed association of CycD1 with regulatory genomic regions
enriched for binding sites of nuclear effectors of growth factor
signaling (5).
Our study provides evidence for a role for CycD2 as a tran-
scription modulator and identifies GATA4 as an important
interacting partner for CycD2 in the heart. The finding that
a cell-specific transcription factor mediates CycD2 recruitment
to DNA-regulatory sequences may provide a paradigm for cell-
specific effects of Cyclin Ds.
Materials and Methods
Plasmids. Plasmids used were either previously described (18, 47, 48) or
obtained by PCR-mediated amplification and cloned in the indicated vector
using standard procedures. Constructs were confirmed by sequencing.
Cell Cultures and Transfections. All cell lines were maintained and transfected
as described previously (18, 47). CDK inhibitor was obtained from Calbiochem
(catalog no. 219476), and RO506220 was obtained from Roche (49).
ChIP. ChIP assays were performed as described previously (18). Primers
sequences are available upon request.
Transgenic Mice. All animal experiments were carried out in accordance with
institutional guidelines for animal care. Experiments were approved by the
institutional Animal Ethics Committee of the University of Ottawa, which
conforms to that of the NIH (assurance no. A5043-01). At end points, mice
were handled as detailed previously (50). Transgenic mice used were fully
characterized in previous reports (18).
Protein and RNA Analysis. Coimmunoprecipitation assays, Western blots, and
electrophoretic mobility-shift assays were carried out using nuclear extracts
from 293T cells overexpressing the appropriate protein as described pre-
viously (51, 52). The immunofluorescence assay was performed as described
previously (53). The primary antibodies used were as follows: anti-Flag M2
(Cell Signaling; 2368) at a 1/700 dilution and anti-CycD2 (Abcam; ab308) at
a 1/500 dilution. The secondary antibodies used were as follows: anti-mouse
Alexa Fluor 488 (Molecular Probes; A-11029) and anti-rabbit Alexa Fluor 546
(Molecular Probes; A-11035), both at a 1/500 dilution. Hoechst staining
(Molecular Probes; H1398) at a 1/5,000 dilution was used to mark nuclei.
Images were taken on Zeiss AxioObserver.D1 microscope.
In Vitro Pull-Down and Kinase Assays. Production of the recombinant GST-
GATA4 proteins and pull-down assays were carried out as described pre-
viously (31, 54). Kinase assay was performed as described previously (54). The
kinases used were as follows: MAPK2 (14-173; Cedarlane); ELK-1 (9184; Cell
Signaling); and CDK4/CycD1 (7530; Cell Signaling).
Xenopus Embryos and Explants. The work with Xenopus was approved by
Cardiff University’s Ethical Review Committee and was carried out under
a license from the United Kingdom Home Office. Xenopus embryos were
obtained and cultured as described previously (55). Details are provided in SI
Materials and Methods.
Statistics. The data are presented as means ± SEM; P < 0.05 by Student t test
is considered statistically significant.
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